AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02586649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a non-active inhalation capsule .
Study NCT02586649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a non-active inhalation capsule .
Study NCT01684865 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.
Study NCT03257319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled titration of morphine chlorhydrate
Description: Patient in arm A will receive 1 to 3 titration
Study NCT03257319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV placebo
Description: Patient in arm A will receive 1 to 6 injection
Study NCT03257319 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Patient in arm B will receive 1 to 3 titration
Study NCT03257319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV titration of morphine chlorhydrate
Description: Patient in arm BA will receive 1 to 6 injection
Study NCT03735446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Checkpoint kinase 1 (CHK1) inhibitor
Study NCT01615913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg terbinafine and 2 mg ketoconazole containing patch
Description: A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
Study NCT01615913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg terbinafine and 2 mg ketoconazole containing patch
Description: A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
Study NCT01615913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 mg terbinafine and 2 mg ketoconazole containing patch
Description: A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2-mg ketoconazole/patch). The average daily released drug amount estimated from in-vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
Study NCT02467686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WHOQOL questionnaire
Description: WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
Study NCT02467686 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: WHOQOL questionnaire
Description: WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
Study NCT02467686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FSFI questionnaire
Description: FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.
Study NCT02467686 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: FSFI questionnaire
Description: FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.
Study NCT02467686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: kupperman scale
Description: Kupperman scale is a tool to help evaluate the severity of menopausal symptoms
Study NCT02467686 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: kupperman scale
Description: Kupperman scale is a tool to help evaluate the severity of menopausal symptoms
Study NCT02467686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimicifuga racemosa
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer
Study NCT02467686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen
Study NCT02467686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tamoxifen
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen
Study NCT02467686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
Study NCT02467686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: exemestane
Description: The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
Study NCT02518295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive control
Description: 200ml milk containing 18g lactose
Study NCT02518295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic S. thermophilus
Description: 200ml milk containing 18g lactose + probiotic S. thermophilus
Study NCT02518295 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic B. longum
Description: 200ml milk containing 18g lactose + probiotic B. longum
Study NCT02518295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative control
Description: 200 ml of UHT Lactose free milk
Study NCT04494997 — intervention group
Intervention type: OTHER
Intervention: Survey Questionnaire
Description: This Cross sectional study uses Questionnaire with Closed ended questions. The survey form is designed using Google forms program. Survey initial question seeks CONSENT from the respondent. Survey collects data under 4 sections.~Section I: Demographic details Section II: 6 Questions regarding use of your Social Media for Professional activities.~Section III: 7 Questions regarding the advantages of your Social Media use. Section IV: 5 Questions regarding the disadvantages of your Social Media use.~The Google form questionnaire survey link will be shared with the Dentists in internet via Social Media \&/Or email to seek responses. The link will be available for single response for a single respondent.
Study NCT01716052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Lactulose
Study NCT01716052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT03404752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Filgrastim
Study NCT03404752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Filgrastim
Study NCT01742117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: One 75 mg tablet per day by mouth for one year
Study NCT01742117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: One 75 mg tablet per day by mouth for one year
Study NCT01742117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: One 90 mg tablet twice per day by mouth for one year
Study NCT02223845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Self-selected music played via headphones
Study NCT04521504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinematic biofeedback with ISEO motion analysis system
Description: Exercises are performed with the help of the ISEO motion analysis system, that provides a real-time biofeedback of shoulder kinematics. All exercises are administered by the Physical Therapist.
Study NCT02670239 — intervention group
Intervention type: PROCEDURE
Intervention: normothermic ex vivo lung perfusion
Study NCT02453347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES Therapy
Description: Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
Study NCT02937324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CloudUPDRS smartphone software assessment
Description: Smartphone software consisting of a series of tapping and tremor-measurement tests designed to measure a subset of the UPDRS.
Study NCT02937324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical assessment
Description: A clinician will assess the motor signs of the participant using the Unified Parkinson's Disease Rating Scale. The examination will be videoed and rated by 3 blinded examiners.
Study NCT01994824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin
Description: Thymoglobulin, 3 mg/kg, will be given on day 8 posttransplant to patients at high risk of significant GVHD per day 7 IL15 and IL2Ra levels.
Study NCT02285608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIMM/SAM
Description: The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
Study NCT02306902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: 130mg, Capsules
Study NCT02306902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTARA® (fenofibrate)
Description: 130mg, Capsules
Study NCT04287296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wakey!
Description: Everyone who has downloaded the app will receive a 9-minute morning show as an alternative to an alarm clock every Mon-Fri for 12 weeks. The show is presented by a cast of presenters who appeal to the target demographic. The intervention content is theory and evidence led, drawing on approaches from cognitive and third-wave psychotherapies, positive psychology interventions (such as those based on resilience training and growth mindset), and lifestyle mental health interventions. Additional content will be provided on the app to support the theory and techniques that are covered in the show. Fun content will also be posted in an ad-hoc manner that complement the shows or relate to cultural dates and aim to increase engagement. Wakey! will avoid any polarising topics such as politics, religion and folk science. There are several features beside the show itself: a moderated live chat between 6-9AM, feedback for users (e.g. how many days they have seen the show, current energy levels).
Study NCT01657240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-118
Description: instill one drop in each eye once a day for 21 days
Study NCT01657240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine Hydrochloride
Description: instill one drop in each eye once a day for 21 days
Study NCT02136069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: 105 mg administered by subcutaneous (SC) injection once every 4 weeks (Q4W) until Week 52.
Study NCT02136069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: 5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
Study NCT02136069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (IV)
Description: Administered by (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
Study NCT02136069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Injection)
Description: Administered by SC injection Q4W until Week 52
Study NCT02350296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSL 40 mg
Description: Ketoprofen lysine salt (KLS) immediate release oral tablets 40 mg, corresponding to 25 mg of ketoprofen free acid. Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design. One (1) tablet of test formulation was administered to the subjects in the morning with 240 mL of still mineral water. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).
Study NCT02350296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKi® 80 mg
Description: OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid). Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design.~The content of half sachet of the reference formulation was dissolved in 190 mL of still mineral water. The subject drank the entire solution immediately. Then the glass was rinsed with 50 mL of still mineral water and the subject drank the rinse immediately. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).
Study NCT02961829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: antiretroviral intensification
Study NCT02961829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: antiretroviral intensification
Study NCT02961829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Therapeutic vaccination
Study NCT02961829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auranofin
Description: purging
Study NCT02961829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirtuin Histone deacetylase inhibitor
Description: latency disruption
Study NCT02299843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RALPPS
Description: Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.
Study NCT02299843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALPPS
Description: Treat the hepatocellular carcinoma with ALPPS.
Study NCT03972943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Receive CPAP treatment
Study NCT03972943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study NCT03972943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03972943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01281800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gemcitabine in long infusion
Description: TREATMENT A:~Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid \[Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT\], vitamin B-12 \[OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT\], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.~TREATMENT B:~Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy.
Study NCT01281800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine in long infusion
Description: TREATMENT A:~Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid \[Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT\], vitamin B-12 \[OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT\], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.~TREATMENT B:~Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy.
Study NCT04733859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: subjects drank 50 ml , 1 bottle a day for 8 week
Study NCT04733859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red djulis drinks
Description: subjects drank 50 ml , 1 bottle a day for 8 week
Study NCT03110770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA090-00-VP
Description: VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV
Study NCT03110770 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VRC-PBSPLA043-00-VP
Description: A sterile phosphate-buffered saline (PBS) prepared for human administration as a placebo
Study NCT03458195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bio-banking collection
Description: blood samples, biopsies, and surgical specimen collected in addition to usual practice
Study NCT04106206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372689
Description: Administered orally
Study NCT04106206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01179113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.
Study NCT01179113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group
Study NCT03879005 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: renal scintigraphy
Description: 99mTc-DTPA Scintigraphy Five mci of 99mTc-DTPA will be injected by IV route together with diuretic. Dose will be adjusted according to the age and weight of the patients. A total of 20 min dynamic imaging followed by calculation of GFR and SRF according to the built-in processing protocol Gate's method.~99mTc-DMSA scintigraphy Five mci of 99mTc- DMSA will be injected by IV route with adjustment according to age and weight. Static images will be acquired in the posterior, anterior, andposterior oblique projections for 60 s each.
Study NCT00419952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (SYMBICORT) pMDI
Description: Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
Study NCT00419952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide HFA pMDI
Description: Budesonide HFA pMDI 160 ug x 2 actuations BID
Study NCT02877589 — intervention group
Intervention type: OTHER
Intervention: hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies and a screening questionnaire to detect risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV)
Study NCT01666041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01666041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate/omega
Study NCT01666041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Study NCT02590224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous bis-glycinate
Study NCT02590224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous glycine sulphate
Study NCT02549365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Description: Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
Study NCT02549365 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surveillance (nasal swabbing) during influenza season
Study NCT02549365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surveillance (nasal swabbing) during influenza season
Study NCT03212781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron dextran
Description: total dose infusion
Study NCT03212781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Fumarate
Description: oral tablets